Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, prog...

Full description

Bibliographic Details
Main Authors:	Melissa Bersanelli, Sebastiano Buti, Roberta Camisa, Matteo Brighenti, Silvia Lazzarelli, Giancarlo Mazza, Rodolfo Passalacqua
Format:	Article
Language:	English
Published:	MDPI AG 2014-09-01
Series:	Cancers
Subjects:	gefitinib interleukin-2 IL-2 lung cancer non-small cell lung cancer NSCLC immunotherapy tyrosine kinase inhibitors TKI
Online Access:	http://www.mdpi.com/2072-6694/6/4/2035

Similar Items

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
by: Naoto Aiko, et al.
Published: (2018-10-01)

Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung
by: Mark H. Cooper
Published: (2018-01-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
by: Xiao Ling Ni, et al.
Published: (2017-01-01)

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2
by: Haibo Cheng, et al.
Published: (2018-11-01)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
by: Ping Chen, et al.
Published: (2019-06-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Urinary Neopterin in Patients Treated with Gefitinib
by: Kalabova Hana, et al.
Published: (2007-02-01)

Drug delivery systems of gefitinib for improved cancer therapy: A review
by: Deepak Nagdiya, et al.
Published: (2023-11-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo
by: Xiaoxia Zhao, et al.
Published: (2021-04-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

Massive pleural effusion and associated pulmonary embolism in a case of Gefitinib responsive lung cancer
by: Rajiv Garg, et al.
Published: (2015-01-01)

Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer
by: Abdelrahman Y. Sherif, et al.
Published: (2023-01-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma
by: Datong CHU, et al.
Published: (2008-02-01)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01)

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
by: Michihito Miyagi, et al.
Published: (2022-12-01)

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
by: Jinjin Shao, et al.
Published: (2024-04-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

Effects of paclitaxel and gefitinib on the proliferation and cell cycle of human lung adenocarcinoma cell SPC-A1
by: Gang JIA, et al.
Published: (2008-06-01)

miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
by: Peng Ge, et al.
Published: (2019-12-01)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
by: Ren Shengnan, et al.
Published: (2022-11-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

Sijunzi Tang improves gefitinib resistance by regulating glutamine metabolism
by: Zhihong Wang, et al.
Published: (2023-11-01)

Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
by: Xiaolong Huang, et al.
Published: (2017-08-01)

Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases
by: Jianping XU, et al.
Published: (2015-09-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan
by: Cheng-Ta Yang, et al.
Published: (2010-01-01)

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer
by: Jian Li, et al.
Published: (2023-02-01)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
by: Fabrizio Gozzi, et al.
Published: (2021-04-01)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017-11-01)

Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
by: Wang Bing, et al.
Published: (2017-06-01)

Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01)

FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer
by: Cong PENG, et al.
Published: (2021-08-01)

Analysis of Prognostic Factors of 80 Advanced NSCLC Patients Treated with Gefitinib for more than 6 Months
by: Ling DAI, et al.
Published: (2010-11-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)